In the past 5–10 years, as the understanding of the molecular mechanisms underlying thyroid cancer has increased, several biomarkers have been developed for the diagnosis of thyroid cancer, including RET/PTC, RAS, and BRAF mutations (11). This evidence concerns the gene BRAF and thyroid cancer.